# Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

> **NCT03574597** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 17604 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT03574597
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-24
- **Primary completion:** 2023-06-21
- **Final completion:** 2023-06-29
- **Target enrollment:** 17604 (ACTUAL)
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574597, "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03574597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*